肥胖症治療神經調控系統市場規模、佔有率和成長分析：按產品類型、應用、最終用戶和地區分類－2026-2033年產業預測

2024年全球用於肥胖治療的神經調控系統市場價值為25億美元，預計將從2025年的27.1億美元成長到2033年的52.1億美元。預測期（2026-2033年）的複合年成長率預計為8.5%。

全球用於治療肥胖症的神經調控系統市場涵蓋了植入式和非侵入式設備，這些設備旨在影響控制食慾、飽腹感和新陳代謝的神經通路。隨著肥胖率的上升，醫療保健系統面臨越來越大的壓力，凸顯了傳統治療方法無法滿足的患者需求。在設備技術創新的推動下，該領域的發展已從胃電刺激設備轉向先進的迷走神經療法。推動該市場發展的關鍵因素是臨床療效與監管核准和保險覆蓋範圍之間關聯性證據的積累，這正在推動更廣泛的應用。此外，人工智慧 (AI) 透過實現自適應控制系統、個人化治療和遠端監測，提高了治療的有效性和可近性，最終為改善患者預後和拓展神經調控療法的臨床路徑鋪平了道路。

全球肥胖症治療神經調控系統市場促進因素

肥胖症盛行率的不斷上升推動了對有效長期解決方案的需求，迫使醫療專業人員探索標準療法以外的替代治療方法。不斷擴大的患者群體推動了對神經調控技術的投資，因為臨床醫生相信這些技術能夠提供持續的體重管理，尤其是在傳統行為療法和藥物療法中效果有限的情況下。隨著人們對肥胖相關嚴重併發症的認知不斷提高，專科醫療機構對基於設備的治療方法的應用正在不斷推進，培訓和轉診流程也不斷加強。因此，製造商正致力於開發和推廣能夠滿足臨床醫生和患者需求的創新解決方案，從而進一步推動市場成長並拓展產品平臺。

全球肥胖症治療神經調節系統市場面臨的限制因素。

全球用於肥胖症治療的神經調控系統市場面臨許多限制因素，阻礙其成長與普及。除了設備和手術相關的高昂初始成本外，不同醫療保險計劃中不明確或有限的報銷選項也對醫院和支付方造成負面影響。這種情況降低了醫療機構將患者轉介至神經調控治療的意願。此外，支付方通常要求提供長期臨床效益和成本效益的全面證據才能批准保險覆蓋，這使得試驗過程複雜化，並為醫療機構和患者都帶來了經濟風險。因此，小規模的診所可能不願投資於專業化和培訓，導致儘管臨床實踐熱情高漲，但其地理擴張緩慢，市場整合程度有限。

全球肥胖症治療神經調控系統市場趨勢

全球用於肥胖治療的神經調控系統市場正經歷著向個人化神經刺激療法的重大轉變。這種療法專注於根據每位患者的生理功能和肥胖表現型客製化刺激參數和設備設定。這種個人化方法，得益於影像和感測技術的進步，能夠實現自適應治療通訊協定，從而增強對食慾和代謝途徑的調節作用。隨著患者療效和生活品質日益受到重視，設備製造商、醫療服務提供者和數位健康平台之間的合作也不斷加強。這有助於實現個人化治療流程，並促進患者持續參與肥胖管理。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

市場考察

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場吸引力指數
• PESTEL 分析
• 監理情勢
• 價值鏈分析
• 監管分析

全球用於肥胖症治療的神經調控系統市場規模：按產品類型和複合年成長率分類（2026-2033 年）

• 植入式神經控制系統
• 非植入式/外在神經調節系統

全球用於肥胖症治療的神經調控系統市場規模：按應用和複合年成長率分類（2026-2033 年）

• 減重管理
• 代謝性疾病治療
• 行為健康干預

全球用於肥胖症治療的神經調控系統市場規模：按最終用戶和複合年成長率分類（2026-2033 年）

• 醫院
• 門診手術中心
• 研究機構
• 居家醫療環境

用於肥胖症治療的神經調控系統全球市場規模及複合年成長率（2026-2033 年）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 2023-2025年營收年比比較

主要企業簡介

• EnteroMedics Inc.
• Intrapace Inc.
• Medtronic plc
• Boston Scientific Corporation
• ReShape Lifesciences Inc.
• Gelesis Inc.
• Dune Medical Devices
• Obesity Surgical Solutions
• Atheromed LLC
• Stimwave LLC
• Nevro Corp.
• Synchrony Health Services
• Ethicon Endo-Surgery
• Apollo Endosurgery Inc.
• Aspire Bariatrics Inc.
• ZeaVision
• VWave LLC
• Intuitive Surgical Inc.
• Echosens
• Minimally Invasive Surgical Technologies

結論與建議

Global Obesity Treating Neuromodulation System Market size was valued at USD 2.5 Billion in 2024 and is poised to grow from USD 2.71 Billion in 2025 to USD 5.21 Billion by 2033, growing at a CAGR of 8.5% during the forecast period (2026-2033).

The global market for obesity-treating neuromodulation systems includes both implantable and noninvasive devices designed to influence neural pathways that govern appetite, satiety, and metabolism. As obesity rates rise, healthcare systems face increased pressure, highlighting the unmet needs of patients with conventional treatments. The evolution of this field has transitioned from gastric electrical stimulators to advanced vagal nerve therapies, supported by innovations in device technology. A critical driver in this market is the growing body of evidence linking clinical efficacy to regulatory approvals and reimbursement, which facilitates broader adoption. Additionally, artificial intelligence enhances treatment efficacy and accessibility by enabling adaptive control systems, personalized treatment, and remote monitoring, ultimately paving the way for better patient outcomes and expanding clinical pathways for neuromodulation therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Obesity Treating Neuromodulation System market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Obesity Treating Neuromodulation System Market Segments Analysis

Global obesity treating neuromodulation system market is segmented by product type, application, end-user and region. Based on product type, the market is segmented into Implantable Neuromodulation Systems and Non-implantable / External Neuromodulation Systems. Based on application, the market is segmented into Weight Loss Management, Metabolic Disorders Treatment and Behavioral Health Interventions. Based on end-user, the market is segmented into Hospitals, Ambulatory Surgical Centers, Research Institutes and Home Care Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Obesity Treating Neuromodulation System Market

The increasing prevalence of obesity is driving a higher demand for effective long-term solutions, leading healthcare professionals to explore alternative treatment options beyond standard approaches. This expanding population of patients is fueling investments in neuromodulation technologies, as there is a belief among clinicians in their potential to provide lasting weight management, particularly where traditional behavioral and pharmacological strategies may fall short. The acknowledgment of serious complications associated with obesity is fostering the adoption of device-based therapies in specialized medical facilities, enhancing training and referral practices. Therefore, manufacturers are focusing on developing and marketing innovative solutions to fulfill the needs of both clinicians and patients, further propelling market growth and expanding the product pipeline.

Restraints in the Global Obesity Treating Neuromodulation System Market

The Global Obesity Treating Neuromodulation System market faces several constraints that hinder its growth and adoption. Significant initial costs associated with devices and procedures, coupled with unclear or restricted reimbursement options in various healthcare systems, negatively impact hospitals and payers. This situation diminishes the likelihood of providers referring patients for neuromodulation treatments. Furthermore, payers often demand comprehensive evidence of long-term clinical advantages and cost-effectiveness prior to granting coverage, complicating the trial process and imposing financial risks on both healthcare institutions and patients. Consequently, smaller clinics may be reluctant to invest in specialized technology and training, resulting in slower geographical expansion and limited market integration despite clinical enthusiasm.

Market Trends of the Global Obesity Treating Neuromodulation System Market

The Global Obesity Treating Neuromodulation System market is witnessing a significant shift towards personalized neurostimulation therapies, which focus on customizing stimulation parameters and device configurations based on individual patient physiology and obesity phenotypes. This tailored approach enhances the modulation of appetite and metabolic pathways, bolstered by advancements in imaging and sensing technologies that inform adaptive treatment protocols. With a growing emphasis on demonstrable improvements in patient outcomes and quality of life, there is a rising collaboration among device manufacturers, healthcare providers, and digital health platforms, paving the way for customized treatment journeys and ongoing patient engagement in obesity management.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Regulatory Analysis

Global Obesity Treating Neuromodulation System Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Implantable Neuromodulation Systems
• Non-implantable / External Neuromodulation Systems

Global Obesity Treating Neuromodulation System Market Size by Application & CAGR (2026-2033)

• Market Overview
• Weight Loss Management
• Metabolic Disorders Treatment
• Behavioral Health Interventions

Global Obesity Treating Neuromodulation System Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Research Institutes
• Home Care Settings

Global Obesity Treating Neuromodulation System Market Size & CAGR (2026-2033)

• North America (Product Type, Application, End-User)
  • US
  • Canada
• Europe (Product Type, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Application, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• EnteroMedics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intrapace Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ReShape Lifesciences Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gelesis Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dune Medical Devices
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Obesity Surgical Solutions
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Atheromed LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stimwave LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nevro Corp.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synchrony Health Services
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ethicon Endo-Surgery
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apollo Endosurgery Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aspire Bariatrics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ZeaVision
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VWave LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intuitive Surgical Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Echosens
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Minimally Invasive Surgical Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations